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Cytomegalovirus (CMV) infection is 1 of the leading causes of morbidity and mortality after allogeneic he-
matopoietic stem cell transplantation (aHSCT), mainly within the ﬁrst 100 days after transplantation. We
aimed to characterize CMV infection in a cohort of 305 patients with different malignancies undergoing
aHSCT at the Portuguese Institute of Oncology of Porto between January 2008 and December 2012. In total,
184 patients (60.3%) developed CMV infection, mainly viral reactivations rather than primary infections
(96.2% versus 3.8%, respectively). The majority of patients (166 of 184) developed CMV infection 100 days
after transplantation, with median time to infection of 29 days (range, 0 to 1285) and median duration of
infection of 10 days (range, 2 to 372). Multivariate analysis revealed that CMV infection was increased in
donor (D)-/recipient (R)þ and Dþ/Rþ (odds ratio [OR], 10.5; 95% conﬁdence interval [CI], 4.35 to 25.4;
P < .001) and in patients with mismatched or unrelated donors (OR, 2.54; 95% CI, 1.34 to 4.80; P ¼ .004). Cox
regression model showed that the risk of death was signiﬁcantly increased in patients >38 years old (OR,
1.89; 95% CI, 1.14 to 3.12; P ¼ .0137), who underwent transplantation with peripheral blood (OR, 3.02; 95% CI,
1.33 to 6.86; P ¼ .008), with mismatched or unrelated donor (OR, 2.16; 95% CI, 1.48 to 3.13; P < .001), and who
developed CMV infection (OR, 1.76; 95% CI, 1.07 to 2.90; P ¼ .025). Moreover, patients who developed CMV
infection had a signiﬁcantly reduced median post-transplantation survival (16 versus 36 months; P ¼ .002).
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Viral infections are currently 1 of the major causes of
morbidity and mortality in patients undergoing hematopoi-
etic stem cell transplantation (HSCT), and therefore, viral
monitoring has a great impact on HSCT patients [1-7].
Cytomegalovirus (CMV) infection is currently recognized as a
leading cause of morbidity and mortality after allogeneic
HSCT (aHSCT), as it is frequently associated with multiorganedgments on page 1965.
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ty for Blood and Marrow Transplantation.disease, including pneumonia, hepatitis, gastroenteritis,
retinitis, and encephalitis [8-12]. Nevertheless, not all in-
dividuals are at the same risk of CMV complication, as the
risk of infection/disease varies with age, source of trans-
plantation, underlying disease, donor (D)/recipient (R) CMV
serological status, and occurrence of graft-versus-host dis-
ease (GVDH) [13,14].
Typically, CMV infection appears within the ﬁrst 100 days
after HSCT and affects mainly the lungs and the gastroin-
testinal tract [4,10,12,15,16]. However, with the introduction
of antiviral drugs, an increasing number of infections occur in
a late period exceeding 100 days after HSCT [7,8]. Hence, the
introduction of reliable and sensitive laboratory tests for
early detection of CMV infection that allow the start of
Table 1
Baseline Characteristics of the Study Population
Variable n (%)
Gender
Female 119 (39.0)
Male 186 (61.0)
Age
20 yr old 82 (26.9)
21-40 yr old 85 (27.9)
>40 yr old 138 (45.2)
Underlying disease
Acute leukemia 161 (52.8)
Chronic myeloproliferative diseases 26 (8.5)
Chronic lymphoproliferative diseases 56 (18.4)
Myelodysplastic/myeloproliferative diseases 28 (8.9)
Aplastic anemia 24 (7.9)
Others 10 (3.6)
Stem cell source
CB 21 (6.9)
BM 27 (8.9)
PBSC 257 (84.2)
Phase at transplantation (n ¼ 284)
First RC 199 (70.1)
RC  second 49 (17.2)
Active disease 36 (12.7)
Conditioning regimen
RIC 120 (39.3)
Myeloablative 185 (60.7)
Donor
Related 185 (60.7)
Mismatched or unrelated 120 (39.3)
Recipient CMV status
Seronegative 42 (13.8)
Seropositive 263 (86.2)
Donor CMV status (n ¼ 303)
Seronegative 81 (26.7)
Seropositive 222 (73.3)
CMV donor/recipient status (n ¼ 303)
D-/R- 21 (6.9)
Dþ/R- 22 (7.3)
D-/Rþ 60 (19.8)
Dþ/Rþ 200 (66.0)
CB indicates cord blood; BM, bone marrow; RC, complete remission.
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of post-transplantation morbidity and mortality [11,17-20].
Despite advances in diagnosis and prevention, CMV
infection it is still considered a major problem for aHSCT
patients [2,10,11,21]. Hence, the aim of the present study was
to retrospectively review and characterize CMV infection
among aHSCT recipients by summarizing the data from
consecutive patients undergoing aHSCT at the Portuguese
Institute of Oncology of Porto (IPO Porto) during the period
of 2008 to 2012.
MATERIAL AND METHODS
Type of Study and Population
We performed a retrospective study in a cohort of 305 patients with
different malignancies undergoing aHSCT at the bone marrow trans-
plantation service from the Portuguese Institute of Oncology of Porto be-
tween January 2008 and December 2012. This study was approved by the
institution ethical committee (ref CES 462/013) and clinical data were
collected retrospectively from the clinical records of patients.
Transplantation Procedures
Transplantation was performed according to institutional protocols
based on international standards for aHSCT. Brieﬂy, the myeloablative
regimen was based on busulfan and cyclophosphamide, whereas the
reduced-intensity conditioning (RIC) was based on a reduced busulfan dose
plus ﬂudarabine. Patients with mismatched or unrelated donors received
antithymocyte globulin as part of the conditioning regimen. GVHD pro-
phylaxis in patients on a myeloablative regimen consisted of a combination
of a calcineurin inhibitor, either cyclosporine (CsA) or tacrolimus, and short-
term methotrexate. Patients using RIC received CsA or tacrolimus plus
mycophenolate mofetil. GVHD prophylaxis was maintained for 6 months
with a progressive reduction of immunosuppression: CsA and tacrolimus
were reduced by one third each month after the third month, and myco-
phenolate mofetil was reduced by one half at day þ29, by one quarter at
day þ57, and suspended at day þ85.
CMV Monitoring after aHSCT
All patients were followed for CMV infection according to the institu-
tional protocol for aHSCT patients. Prospective post-transplantation CMV
monitoring was performed in peripheral blood samples starting at day of
transplantation with biweekly analysis up to 100 days or longer if compli-
cations were present, weekly up to 180 days, bimonthly up to 1 year, and
after the ﬁrst year on routine evaluations.
CMV infection monitoring was performed on whole blood samples by
pp65 antigenemia assay, with the C10/C11 monoclonal antibody cocktail (IQ
Products, Groningen, Netherlands) to detect the CMV lower matrix phos-
phoprotein (pp65) or, if WBC count was<1000/mL by quantitative real-time
PCR using the Q-CMV Real Time Complete kit (ELITech Group, Puteaux,
France).
Management of Post-aHSCT CMV Infection
All patients were followed using a preemptive strategy for CMV disease
prevention. Institutional cut-off for initiation of preemptive antiviral ther-
apy during the ﬁrst 100 days after aHSCT was based on pp65 antigenemia
results. Preemptive anti-CMV therapy was initiated after the detection of2
antigen-positive cells per 5.0 104 leukocytes or>1000 copies/mLwith oral
valganciclovir (VGCV) at a dose of 900 mg twice a day for 14 days as in-
duction therapy. In the context of gastrointestinal intolerance, oral VGCV
was substituted with intravenous ganciclovir (GCV) at a dose of 5 mg/kg
twice daily for 14 days. All patients received one-half dose of antiviral (VGCV
900mg or GCV 5mg/kg once a day) as a maintenance therapy until negative
CMV detection or day 100. Patients with severe VGCV- or GCV-associated
cytopenia were treated with intravenous foscarnet at a dose of 60 mg/kg/
8 hours for 14 days. Antiviral doses were closely monitored according to
patients’ renal function and results from pp65 antigenemia or CMV
viral load.
Variable Deﬁnitions
Hematological diseases were classiﬁed into the following categories: (1)
acute leukemia (acute myeloid leukemia, acute lymphoid leukemia), (2)
chronic myeloproliferative disorders (chronic myeloid leukemia, poly-
cythemia vera, myeloﬁbrosis), (3) chronic lymphoproliferative disorders (B
cell lymphoma, T cell lymphoma, multiple myeloma, chronic lymphoid
leukemia), (4) myelodysplastic syndrome (chronic myelomonocytic leuke-
mia), (5) aplastic anemia (Fanconi anemia, dyskeratosis congenita,Diamond-Blakfan syndrome), and (6) others (metabolic disease, hemoglo-
binopathies). The status of disease at the time of aHSCT was classiﬁed as
follows: (1) ﬁrst complete remission or inactive disease after the ﬁrst-line
treatment, (2) second or following complete remission after equal or
greater than second-line treatment, and (3) relapse or active disease.
The primary endpoint of this study was to characterize CMV infection
after aHSCT. CMV infection was deﬁned as a positive result in either pp65
antigenemia (1 antigen-positive cell per 5.0  104 leukocytes) or real-time
PCR (viral load in whole blood sample 100 copies/mL). Time to infection
(TTI) was deﬁned as the difference between the day of aHSCT and the day of
ﬁrst CMV positive result. Duration of infection (DOI) was deﬁned as the dif-
ference between the day of ﬁrst positive CMV result and the day of last
positive CMV result (that is, the positive result preceding 4 consecutive
negative results during biweekly monitoring). Early CMV infection was
deﬁned as occurring before 100 days after aHSCT, whereas late CMV infection
was deﬁned as occurring after 100 days from aHSCT.
The outcomes analyzed were engraftment, disease relapse, and mor-
tality. Acute GVHD (aGVHD) was deﬁned as occurring during the 100 days
after transplantation, and chronic GVHD (cGVHD) was deﬁned as occurring
after 101 days from transplantation. Successful engraftment of trans-
plantationwasmeasured by neutrophil and platelet recoveries, here deﬁned
as the ﬁrst of 3 consecutive days during which the neutrophil and platelet
count in blood were over .5  109/L and 20  109/L, respectively, without
transfusion support. Disease relapse was deﬁned clinically. Post-trans-
plantation survival (PTS) was deﬁned as the time between the day of HSCT
and the day of the last visit to hospital or the day of death.
Statistical Analysis
Statistical analysis was performed with IBM SPSS Statistics for Macin-
tosh, Version 20.0 (IBM Corp., Armonk, NY). Chi-square or Fisher exact test
were used to compare the categorical variables with a 5% signiﬁcance level.
Univariate analysis and multivariate logistic regression models were used to
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(CIs) as a measure of association between the categorical variables, GVHD
development, and CMV infection. Multivariate analyses were performed by
adjusting for the following covariates: gender, median age at aHSCT, stem
cell source, phase at transplantation, conditioning regimen, donor/recipient
CMV serological status, HLA mismatch, and, when applicable, GVHD
development and CMV infection. Continuous variables were tested for
normality with Kolmogorov-Smirnov Test and nonparametric tests (Mann-
Whitney U-test) were used for non-normally distributed variables (TTI and
DOI). Cox proportional hazard models (univariate and multivariate) were
used to assess the risk factors associated with TTI, DOI, disease relapse, and
death by estimating hazard ratios and the corresponding 95% CIs. The
Kaplan-Meier method with log-rank test was used to calculate the associ-
ation between CMV infection and PTS.RESULTS
Characteristics of the Study Population
Clinical variables collected from both patients and donors
are summarized in Table 1. In our case series, the median age
at aHSCT was 38 years (range, 0 to 66) with 82 patients
<18 years of age, 85 patients between 21 and 40 years of age,
and 138 patients >40 years of age. The majority of patients
underwent aHSCT for acute leukemia (n ¼ 161, 52.8%) fol-
lowed by chronic lymphoid disease (n ¼ 56, 18.4%). Periph-
eral blood was the ﬁrst choice of source of stem cells in 257
cases (84.3%) and related donors were used in 190 cases
(62.3%). One hundred and eighty-ﬁve (60.7%) underwent
myeloablative conditioning regimen before transplantation
and 199 were in ﬁrst complete remission (70.1%). CMV
serological status showed that the majority of both patients
and donors were seropositive for CMV (n ¼ 200, 67.1%).GVHD
In our study, a total of 226 patients developed GVHD
(75.1%), with 160 (70.8%) aGVHD and 66 (29.2%) cGVHD. WeTable 2
Characterization of GVHD Occurring among aHSCT Recipients
Risk Factor GVHD n (%) P Value*
Gender
Female (n ¼ 117) 86 (73.5) .614
Male (n ¼ 184) 140 (76.1)
Age
38 (n ¼ 152) 107 (70.4) .058
>38 (n ¼ 149) 119 (79.9)
Stem cell source
CB or BM (n ¼ 47) 28 (59.6) .007
PBSC (n ¼ 254) 198 (78.0)
Phase at transplantation
RC1 (n ¼ 199) 155 (77.9) .055
RC  second or active (n ¼ 85) 57 (67.1)
Conditioning regimen
RIC (n ¼ 118) 79 (66.9) .009
Myeloablative (n ¼ 183) 147 (80.3)
Donor/HLA status
Related (n ¼ 183) 137 (74.9) .913
Mismatched or unrelated (n ¼ 118) 89 (75.4)
Recipient CMV status
Seronegative (n ¼ 42) 30 (71.4) .555
Seropositive (n ¼ 259) 196 (75.7)
Donor CMV status
Seronegative (n ¼ 81) 56 (69.1) .160
Seropositive (n ¼ 218) 168 (77.1)
Donor/recipient CMV status
D-/R- (n ¼ 21) 17 (81.0) .044z
Dþ/R- (n ¼ 22) 14 (63.6)
D-/Rþ (n ¼ 60) 39 (65.0)
Dþ/Rþ (n ¼ 196) 154 (78.6)
* Univariate analysis.
y Multivariate logistic regression analysis.
z The analysis was performed considering D-/R-, Dþ/R-, and D-/Rþ versus Dþ/Robserved that of the 160 patients with aGVHD, 97 (60.6%)
developed aGVDH  grade 2 and 102 (63.8%) progressed to
cGVHD.
The characterization of GVHD according to clinical vari-
ables is shown in Table 2. Univariate analysis revealed that
GVHD was more frequent in patients receiving peripheral
blood as the source of stem cells (P ¼ .007) under myeloa-
blative conditioning (P¼ .009) and in CMV Dþ/Rþ (P¼ .044).
The multivariate logistic regression analysis conﬁrmed that
patients receiving stem cells from peripheral blood (OR, 2.84;
95% CI, 1.31 to 6.17; P ¼ .008) with myeloablative condi-
tioning (OR, 2.04; 95% CI, 1.06 to 3.94; P ¼ .033) were asso-
ciated with increased risk of developing GVHD, and patients
in second complete remission or active disease had almost
50% reduction in the probability of developing GVHD (OR,
.53; 95% CI, .28 to .99; P ¼ .048). Moreover, the analysis
conﬁrmed the tendency for increased risk of GVHD devel-
opment in patients >38 years of age (OR, 1.94; 95% CI, .97 to
3.87; P ¼ .062).
CMV Infection
Our case series revealed that 184 patients (60.3%) devel-
oped CMV infection, consisting in great majority of viral
reactivations rather than primary infections (96.2% versus
3.8%, respectively). Table 3 details the statistical analysis of
the association of CMV infection with clinical variables. The
statistical analysis revealed no signiﬁcant association of CMV
infection development with gender, age, underlying disease,
stem cell source, phase at transplantation, conditioning
regimen, donor CMV seropositivity, and GVHD development.
Nevertheless, the risk of CMV infection was signiﬁcantly
increased in CMV seropositive recipients (P < .001; OR, 10.3;
95% CI, 4.39 to 24.1). When considering the D/R CMVOR* (95% CI) P Valuey ORy (95% CI)
1.15 (.67-1.95) .874 1.05 (.58-1.88)
1.67 (.98-2.84) .062 1.94 (.97-3.87)
2.40 (1.25-4.61) .008 2.84 (1.31-6.17)
.58 (.33-1.01) .048 .53 (.28-.99)
2.02 (1.19-3.42) .033 2.04 (1.06-3.94)
1.03 (.60-1.76) .274 1.46 (.74-2.89)
1.24 (.60-2.58)
1.50 (.85-2.65)
1.73 (1.01-2.96) .164 1.55 (.84-2.88)
þ.
Table 3
Analysis of CMV Infection among aHSCT Recipients
Risk Factor CMV Infection n (%) P Value* OR* (95% CI) P Valuey ORy (95% CI)
Gender
Female (n ¼ 119) 72 (60.5) .960 .99 (.62-1.58) .791 1.08 (.63-1.84)
Male (n ¼ 186) 112 (60.2)
Age
38 (n ¼ 153) 88 (57.5) .314 1.26 (.80-2.00) .338 1.34 (.73-2.48)
>38 (n ¼ 152) 119 (63.2)
Stem cell source
CB or BM (n ¼ 48) 30 (62.5) .738 .90 (.48-1.69) .300 .65 (.28-1.47)
PBSC (n ¼ 257) 154 (59.9)
Phase at transplantation
RC1 (n ¼ 199) 115 (57.8) .367 1.27 (.75-2.15) .243 1.44 (.78-2.68)
RC  second or active (n ¼ 85) 54 (53.5)
Conditioning regimen
RIC (n ¼ 120) 74 (61.7) .700 .91 (.57-1.46) .368 .76 (.42-1.38)
Myeloablative (n ¼ 185) 120 (59.5)
Donor/HLA status
Related (n ¼ 185) 104 (56.2) .068 1.56 (.97-2.51) .004 2.54 (1.34-4.80)
Mismatched or unrelated (n ¼ 120) 80 (66.7)
Recipient CMV status
Seronegative (n ¼ 42) 7 (16.7) <.001 10.3 (4.39-24.1)
Seropositive (n ¼ 263) 177 (67.3)
Donor CMV status
Seronegative (n ¼ 81) 46 (56.8) .438 1.23 (.73-2.05)
Seropositive (n ¼ 222) 137 (61.7)
Donor/recipient CMV status
D-/R- (n ¼ 21) 3 (14.3) <.001z 7.64 (3.51-16.6) <.001z 10.5 (4.35-25.4)
Dþ/R- (n ¼ 22) 6 (27.3)
D-/Rþ (n ¼ 60) 43 (71.7)
Dþ/Rþ (n ¼ 200) 131 (65.5)
GVHD
Absent (n ¼ 75) 40 (53.3) .127 1.51 (.89-2.56) .127 1.62 (.87-3.03)
Present (n ¼ 226) 143 (63.3)
Chronic (n ¼ 66) 37 (56.1) .148 1.53 (.86-2.76)
Acute (n ¼ 160) 106 (66.3)
Acute grade <2 (n ¼ 42) 26 (61.9) .561 1.25 (.59-2.65)
Acute grade 2 (n ¼ 97) 65 (67.0)
* Univariate analysis.
y Multivariate logistic regression analysis.
z The analysis was performed considering D-/R-, Dþ/R-, and D-/Rþ versus Dþ/Rþ.
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tribution (P < .001); nevertheless, we observed that there
were no differences between D-/R- and Dþ/R- (P ¼ .252) and
between D-/Rþ and Dþ/Rþ (P ¼ .373). In fact, we observed a
signiﬁcant difference when comparing D-/R- and Dþ/R-
versus D-/Rþ and Dþ/Rþ (P  .001; OR, 7.64; 95% CI, 3.51 to
16.6). Moreover, and despite not being statistically signiﬁ-
cant, the prevalence of CMV infection tended to be higher
among mismatched or unrelated donors (67.0% versus 56.0%,
respectively) (P ¼ .068; OR, 1.56; 95% CI, .97 to 2.51).
The multivariate logistic regression adjusting the analysis
for covariates revealed an over 10-fold increased risk for CMV
reactivation for D-/Rþ and Dþ/Rþ patients (P < .001; OR,
10.5; 95% CI, 4.35 to 25.4) and aHSCT with mismatched or
unrelated donors (P ¼ .004; OR, 2.54; 95% CI, 1.34 to 4.80).Kinetics of CMV Infection
Considering the TTI, we observed that 166 patients
(54.4%) in our cohort developed early CMV infection
(100 days after transplantation) and only 18 patients (5.9%)
developed late CMV infection (>100 days after trans-
plantation). In our series, the median TTI was 29 days (range,
0 to 1285) and the median DOI was 10 days (range, 2 to 372).
Univariate and multivariate analyses were used to char-
acterize the clinical variables that were associatedwith time-
dependent characteristic of CMV infection (Table 4).Cox regression analysis showed that the median TTI was
signiﬁcantly longer in patients >38 years old (36.0 versus
27.0 days, P ¼ .02), those receiving peripheral blood as the
source of graft (33.0 versus 23.5 days, P ¼ .001), those un-
dergoing RIC (34.5 versus 28.0 days, P ¼ .009), those with
related donors (40.0 versus 22.0 days, P < .001), and those
with CMV-seropositive donors (33.0 versus 24.0 days,
P ¼ .012). However, when performing multivariate analysis,
combining all information, the results showed that TTI was
only associated with donor/HLA status (P < .001).
In addition, we observed that the median DOI was
signiﬁcantly longer in patients  38 years of age (11.0 versus
7.0 days, P ¼ .017), those receiving cord blood or bone
marrow transplants (20.5 versus 8.0 days, P ¼ .011), those
with mismatched or unrelated donors (20.0 versus 7.0 days,
P < .001), and those with CMV-seronegative donors (14.0
versus 8.0 days, P < .001). When performing multivariate
analysis, the results showed that DOI was only associated
with donor/HLA status (P < .001) and with CMV Dþ/Rþ
(P ¼ .029).Patient Outcomes
The median time of hospitalization was 29 days (range, 9
to 395) and the overall median follow-up time after trans-
plantation of our case series was 22 months (range, 0 to 68).
Regarding the success of engraftment, we observed that the
291 patients had neutrophil counts>.5109/L, whereas only
Table 4
Analysis of CMV Infection Kinetics among aHSCT Recipients
TTI, Median (IQR), d P Value* DOI, Median (IQR), d P Value*
Gender
Female (n ¼ 72) 28.5 (19.0-47.0) .360 9.5 (2.0-21.0) .764
Male (n ¼ 112) 32.0 (22.0-49.0) 11.0 (2.0-28.0)
Age
38 (n ¼ 88) 27.0 (18.0-40.0) .020 11.0 (2.2-30.8) .017
>38 (n ¼ 96) 36.0 (23.5-54.8) 7.0 (2.0-20.0)
Stem cell source
CB or BM (n ¼ 30) 23.5 (17.0-36.0) .001 20.5 (7.8-52.2) .011
PBSC (n ¼ 154) 33.0 (22.0-50.5) 8.0 (2.0-21.0)
Phase at transplantation
RC1 (n ¼ 115) 32.0 (21.0-49.0) .810 10.0 (2.0-21.0) .929
RC  second or active (n ¼ 54) 34.5 (22.0-52.5) 12.0 (2.0-20.2)
Conditioning regimen
Myeloablative (n ¼ 110) 28.0 (18.0-41.3) .009 10.0 (2.0-25.0) .597
RIC (n ¼ 74) 34.5 (23.8-60.0) 12.5 (2.0-24.0)
Donor/HLA status
Related (n ¼ 104) 40.0 (27.0-60.0) <.001 7.0 (2.0-15.0) <.001
Mismatched or unrelated (n ¼ 80) 22.0 (17.0-32.0) 20.0 (7.0-41.2)
Recipient CMV status
Seronegative (n ¼ 7) 47.0 (18.0-54.0) .603 17.0 (2.0-99.0) .497
Seropositive (n ¼ 177) 29.0 (21.0-47.0) 10.0 (2.0-24.0)
Donor CMV status
Seronegative (n ¼ 44) 24.0 (18.0-39.5) .012 14.0 (7.0-52.8) <.001
Seropositive (n ¼ 137) 33.0 (22.0-50.5) 8.0 (2.0-19.5)
Donor/recipient CMV status
D-/R-, Dþ/R- (n ¼ 9) 46.0 (16.0-52.5) .922 21.0 (2.5-110.5) .198
D-/Rþ, Dþ/Rþ (n ¼ 174) 29.0 (21.0-47.0) 10.0 (2.0-21.5)
GVHD
Absent (n ¼ 40) 28.0 (21.0-41.8) .231 8.5 (2.0-24.8) .634
Present (n ¼ 143) 32.0 (21.0-49.0) 10.0 (2.0-23.0)
Chronic (n ¼ 37) 32.0 (25.0-41.5) .208 6.0 (2.0-18.5) .534
Acute (n ¼ 106) 32.5 (18.8-56.0) 12.0 (3.0-25.0)
Acute grade <2 (n ¼ 26) 25.5 (18.8-40.0) .056 8.0 (2.8-21.0) .207
Acute grade 2 (n ¼ 65) 38.0 (21.0-66.0) 14.0 (2.5-25.0)
IQR indicates interquartile range.
* Cox regression analysis.
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engraftment success was 85.2% (260 of 305). Univariate (OR,
3.78; 95% CI, 1.93 to 7.39; P < .001) and multivariate (OR,
4.08; 95% CI, 1.78 to 9.38; P ¼ .001) analysis revealed that
engraftment success was only signiﬁcantly associated with a
myeloablative regimen (data not shown). Themedian time to
neutrophil engraftment was 14 days (range, 1 to 95) and
median time to platelet engraftment was 13 days (range, 1 to
377). Statistical analysis showed no correlation between
CMV infection and time to neutrophil (P ¼ .882) or platelet
(P ¼ .103) engraftment.
Disease relapse was observed in 73 patients (23.9%)
within a median of 5 months (range, 0 to 45). Univariate and
multivariate Cox regression analyses were used to charac-
terize the clinical variables that were associated with disease
relapse (Table 5) and no statistical signiﬁcant associationwas
found. Nevertheless, the multivariate analysis revealed a
tendency to increased risk of relapse associated with pe-
ripheral blood as the source of graft (OR, 7.84; P ¼ .071) and
with complete remission  second or active disease at the
time of transplantation (OR, 1.70; P ¼ .076).
At the end of the follow-up period, 194 patients (63.6%)
were still alive with a median follow-up of 37 months (range,
2 to 68). To characterize the variables potentially associated
with mortality, both univariate and multivariate analyses
were performed (Table 5). The univariate analysis revealed
that the risk of death was signiﬁcantly increased in patients
who underwent aHSCT with peripheral blood (OR, 2.16; 95%
CI, 1.13 to 4.13; P ¼ .020), with mismatched or unrelated
donor (OR, 2.48; 95% CI, 1.53 to 4.01; P < .001), whodeveloped aGVHD (OR, 2.22; 95% CI, 1.22 to 4.04; P¼ .009), or
who developed CMV infection (OR, 1.90; 95% CI, 1.26 to 2.87;
P ¼ .002). In addition, the multivariate Cox regression anal-
ysis conﬁrmed that the risk of death was signiﬁcantly
increased in patients with CMV infection (OR, 1.76; 95% CI,
1.07 to 2.90; P ¼ .025), older than 39 years (OR, 1.89; 95% CI,
1.14 to 3.12; P ¼ .013), submitted to aHSCT with peripheral
blood (OR, 3.02; 95% CI, 1.33 to 6.86; P ¼ .008), or with
mismatched or unrelated donor (OR, 2.16; 95% CI, 1.48 to
3.13; P < .001). On the other hand, patients who developed
GVHD have a signiﬁcant decreased risk of death (OR, .47; 95%
CI, .30 to .75; P ¼ .002).
Overall, in our case series, we observed that patients who
developed CMV infection had signiﬁcantly reduced post-
transplantation survival (median, 16.0 versus 36.0 months;
P ¼ .002) (Figure 1).
DISCUSSION
Viral infections remain 1 of the most important compli-
cations after aHSCT, with different impacts, depending on the
moment of acquisition: infections caused by herpes simplex
virus and hepatitis B and C viruses appear usually within the
ﬁrst month after transplantation, CMV is frequent between
the ﬁrst and fourth month after transplantation, and other
latent viruses such as varicella-zoster virus and Epstein-Barr
virus appear mainly between the second and sixth months
after transplantation [4,15,22,23].
In this study, we intended to characterize the occurrence
of CMV infection in 305 consecutive and unselected Portu-
guese patients undergoing aHSCT at the Portuguese
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Figure 1. Association between CMV infection and post-transplantation survival in aHSCT patients. Kaplan-Meier plots with log-rank test estimate the post-
transplantation survival of aHSCT patients with and without CMV infection.
H. Sousa et al. / Biol Blood Marrow Transplant 20 (2014) 1958e19671964Institute of Oncology of Porto. These data have not been
reported previously, and although limited by its retrospec-
tive design, the study was able to include all patients sub-
mitted to aHSCT over a 5-year period. Regarding our case
series, we observed that the majority of patients were male
adults with a diagnosis of acute leukemia. The majority of
aHSCT was performed with peripheral blood from related
donors and a myeloablative regimen was used as the most
frequent conditioning regimen. The rate of successful
engraftment was 85.2%, disease relapse was observed only
in 23.9% of patients, and overall mortality was 37.4%.
Moreover, the follow-up period was very long for the ma-
jority of patients, considering that, in our case series, the
majority of CMV reactivation occurred during the ﬁrst
100 days after transplantation or within the ﬁrst year
[18,24].
Our results showed that the overall prevalence of CMV
infection in aHSCT patients was 60.3%. These data point to a
relatively high prevalence of CMV infection in our series.
Nevertheless, the prevalence of CMV infection in aHSCT
differs from study to study according to some population
speciﬁcities: source of graft, age of patients, type of under-
lying disease, and conditioning regimen [25-28]. Despite
some differences in the frequencies, we observed that CMV
infection was not associated with gender, age at trans-
plantation, underlying disease, stem cell source, phase at
transplantation, conditioning regimen, and donor CMV
seropositivity (see also supplementary table). Some authors
state that CMV infection is more frequent in peripheral blood
stem cells (PBSC) graft recipients rather than in cord blood or
bone marrow recipients [29-32], although these data do not
seem to be clear, as some authors state no difference [33].Moreover, the use of RIC has been also described as corre-
lated with increased susceptibility to CMV infection, as pa-
tients were more prone to viral reactivation in neutrophils.
Nevertheless, the data analysis revealed that CMV infection
was signiﬁcantly more common in CMV D-/Rþ and Dþ/Rþ
patients (66.9% versus 20.9%; OR, 7.64) and in mismatched or
unrelated donors (66.7% versus 56.2%; OR, 2.21). Risk factors
for CMV infection after aHSCT have been widely studied and
the majority of studies showed that CMV seropositivity and
mismatched or unrelated donors are consistently associated
with increased risk of reactivation [11,21,27,34-38]. It has
been suggested that there is a signiﬁcant increase of immu-
nosuppression in patients with mismatched or unrelated
donors and, therefore, the reactivation of CMV is expected to
be more frequent [39]. Hence, these data reinforce the need
of implementation of effective prophylactic or preemptive
measures with a correct assessment of the risk of CMV
reactivation for each patient [11,40-42].
Literature states that CMV reactivation occurs mainly in
the ﬁrst 100 days after transplantation [18,24,27,30,34], and
in our study we observed that the majority of patients
developed CMV infection during this period (90.2% versus
9.8%). In our series, the median TTI was 29 days, which is
consistent with other reports that show similar results,
supporting the evidence that CMV reactivation is more
frequent during the period of higher immunosuppression
[18,27,39]. In addition, we have found that patients38 years
old who underwent myeloablative regimen with cord blood
or bone marrow grafts from mismatched or unrelated CMV-
seronegative donors had reduced TTI. Nevertheless, the use
of different methodologies for CMV detection may have a
great impact on the sensitivity of diagnosis and, therefore,
H. Sousa et al. / Biol Blood Marrow Transplant 20 (2014) 1958e1967 1965have an impact on the efﬁciency of treatment; however,
intra- and interlaboratory variability has been challenging
clinicians [11,43,44]. In our institution, the detection of CMV
is mainly based on the pp65 antigenemia, with PCR detection
only performed in cases where pp65 antigenemia is not
possible. Nevertheless, several reports have showed that
molecular techniques are more sensitive and, therefore, can
detect viral reactivation earlier than pp65 antigenemia
[42,44,45]. There has been a large discussion regarding the
best approach for CMV detection because its utility has an
impact on preemptive treatment, and the major problem is
still the deﬁnition of a clinical cut-off value for the imple-
mentation of preemptive treatment [42,44,46]. Recently,
Cardenoso et al. have shown a relevant correlation of pp65
antigenemia with CMV viral load, which requires more
studies to evaluate the intra- and inter-laboratory perfor-
mance [44].
In our case series, we observed that the median DOI was
10 days and that it was more prolonged in patients38 years
old who underwent transplantation with cord blood or bone
marrow grafts from mismatched or unrelated CMV-
seronegative donors. In fact, CMV infection is thought to be
more complicated in some patients and, therefore, a correct
treatment approach is required. In our institution, preemp-
tive strategy for CMV disease prevention is preferred to
prophylactic approach as it has been shown that the use of
prophylactic antiviral drugs is associated with a delay in the
recovery of the cellular immune response critical to the
control of viral infection and, therefore, might increase the
risk of infection in some patients [18,24]. Moreover, there is a
discussion of which is the best approach for the prevention of
CMV reactivation: acyclovir/valacyclovir or GCV/VGCV.
Although literature indicates that the most effective
approach seems to be the use of intravenous GCV [11], in our
institution, oral VGCV is the preferred drug to avoid some of
the severe consequences of GCV (myelotoxicity and renal
toxicity), whereas GCV is reserved for cases of gastrointes-
tinal intolerance. In fact, VGCV, the oral prodrug of GCV, has
been shown to be efﬁcient in preemptive treatment of CMV
infections in aHSCT patients without signiﬁcant toxicity [47].
These differences in either prophylactic or preemptive
approach and ﬁrst-line treatment choice reinforce the need
of guidelines for patients undergoing HSCT, similar to those
that have been reported for solid organ transplants re-
cipients [48,49].
Our study revealed that post-HSCT disease relapse was
present in 23.9% of cases. In fact, disease relapse is a rela-
tively frequent event, ranging from 30% to 70%, and is
dependent on the several factors, including disease status at
the time of transplantation, donor source, and conditioning
regimen [50-52]. Recently, a study from Elmaagacli et al. has
shown that CMV reactivation was associated with reduced
risk of relapse in patients with acute myeloid leukemia [53]
and actually, these results were corroborated by a few au-
thors who describe similar evidence [26,42,54]. In our study,
we observed no associationwith disease relapse, except for a
tendency regarding the use of peripheral blood as stem cell
source or the presence of second complete remission or
active disease at the time of transplantation. Moreover, we
observed no signiﬁcant differences regarding disease relapse
and CMV infection according to the underlying disease (data
not shown). The evidence in the literature has led to a great
discussion regarding the possibility that CMV infection could
have an antileukemic effect by infecting leukemic cells, and
that still must be elucidated [55].GVHD is also a signiﬁcant cause of morbidity and mor-
tality in aHSCT patients and, in fact, CMV infection seems to
be frequently found concomitantly with the presence of
gastrointestinal GVHD [21,56]. Nevertheless, in our case se-
ries, we found no signiﬁcant association of CMV infection
with GVHD development. Despite the fact that GVHD was a
frequent event observed in our case series, with a total of 226
patients developing either aGVHD or cGVHD, it was more
frequent in patients receiving transplants of PBSC with
myeloablative conditioning. In fact, the literature indicates
that transplants of PBSC are associated with increased risks
of both severe aGVHD and cGVHD [57,58]. Moreover, it has
been widely described that RIC regimens allow a translation
from host to donor immune system without the develop-
ment of GVHD, contrary to myeloablative regimens [59,60].
Despite the existent consensus regarding some of the GVHD
predisposing factors, we are still lacking guidelines for
the standardization of risk assessment and therapeutic
strategy [57].
Although pneumonia and gastrointestinal disease are the
most frequent clinical manifestations in aHSCT recipients,
CMV infection is highly associated with mortality [8-
10,21,61]. In agreement with literature, our case series
showed that patients who developed CMV infection had a
signiﬁcantly reduced median post-transplantation survival
(16.0 versus 36.0 months). In the past 20 years, several
studies stated that CMV infection is consistently associated
with increased morbidity and mortality in aHSCT patients
[10,11,21]. In fact, we veriﬁed that in our case series, the risk
of death in patients with CMV infection is increased 2-fold
compared with those without CMV infection.
To the best of our knowledge, this is the ﬁrst study
reporting CMV infection among aHSCT recipients in Portugal.
By performing a retrospective review at the Portuguese
Institute of Oncology of Porto between 2008 and 2012, we
have included data from a large cohort of patients who un-
derwent aHSCT. Our study revealed that CMV infectionwas a
frequent event, especially in CMV-seropositive recipients
and patients with mismatched or unrelated donors. More-
over, we have identiﬁed several factors that affect the me-
dian TTI and DOI of CMV infection, and, therefore, we now
have important data that should be used to select patients
who will beneﬁt from speciﬁc prophylactic or preemptive
strategies. Finally, as CMV infectionwas revealed to be highly
correlated with mortality of aHSCT patients, it is extremely
important to increase attention to the selection of more
sensitive CMV detection methods and better treatment op-
tions to avoid CMV-associated morbidity and mortality.
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